Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.34 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 5/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044060 | 0.84 | HCAR3 (0.33) | KDM4EHCAR3HPGDHCAR2 | |
| SCHEMBL6044080 | 0.78 | KEAP1 (0.33) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044534 | 0.78 | HCAR3 (0.35) | HCAR3HPGDHCAR2 | |
| SCHEMBL6685411 | 0.76 | KDM4C (0.39) | KDM4EASPHKDM8HCAR3HPGD | |
| SCHEMBL6044112 | 0.74 | HCAR3 (0.43) | KDM4EASPHKDM8HCAR3HPGD | |
| SCHEMBL6044720 | 0.71 | HCAR3 (0.51) | HCAR3IDH1PTGER4 | |
| SCHEMBL6044683 | 0.70 | HCAR3 (0.36) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044186 | 0.70 | HCAR3 (0.42) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044709 | 0.70 | HCAR3 (0.69) | HCAR3HPGDHCAR2 | |
| SCHEMBL6043987 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | KDM4E 3399/4885ASPH 1496/4885KDM8 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.